Crescendo Biologics: $32 Million Raised To Develop Targeted T Cell Enhancing Therapeutics
By Dan Anderson ● Aug 3, 2023
Crescendo Biologics Ltd - a clinical stage immuno-oncology company developing novel targeted T cell enhancing therapeutics - recently announced that it plans to augment the ongoing Phase 1b clinical trial of CB307 through the addition of a new pembrolizumab (anti-PD-1) combination expansion cohort. An additional financing of $32 million has been secured with the support of all major existing shareholders, including Sofinnova Partners, Andera Partners, IP Group BioNTech, Takeda, and Quan Capital, and new investor Kreos Capital to fund the additional combination expansion arm of the adaptive clinical protocol.